# Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer

> **NCT02605226** · NA · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 240 (estimated)

## Conditions studied

- Stage III Prostate Cancer

## Interventions

- **PROCEDURE:** Cryoablation therapy
- **RADIATION:** External beam radiation therapy
- **DRUG:** bicalutamide
- **DRUG:** luteinizing-hormone releasing-hormone (LHRH) agonist

## Key facts

- **NCT ID:** NCT02605226
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2017-06-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605226, "Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02605226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*